Innovation Pharmaceuticals Inc (IPIX)

$0.00 0.00 (-30.00%)
Market Cap N/A
Revenue (ttm) 0.00
Net Income (ttm) 0.00
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio N/A
Volume 49,700
Avg Vol 388,838
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K 13%
Beta N/A
Analysts Strong Buy
Price Target N/A

Company Profile

Innovation Pharmaceuticals Inc., a clinical stage biopharmaceutical company, develops small molecule therapies to treat inflammatory diseases, cancer, dermatology, and anti- infective. Its lead drug candidate is Brilacidin, a therapeutic for the treatment of oral mucositis, inflammatory bowel disease, acute bacterial skin and skin structure infection, and COVID-19. The company has a license agreement with Alfasigma S.p.A.; and collaborative research agreement with Fox Chase Chemical Diversity Ce...

Industry: Biotechnology
Sector: Healthcare
Phone: 978 921 4125
Address:
301 Edgewater Place, Suite 100, Wakefield, United States
toolajittooquit
toolajittooquit Jan. 20 at 3:47 PM
$IPIX 2026 will be the year to finally write off this stock.
1 · Reply
fit007
fit007 Jan. 13 at 6:26 PM
$IPIX Looks like brilacidin is on this report. https://neuinfo.org/data/record/nlx_144509-1/RRID:SCR_008143/resolver/pdf&i=rrid:scr_008143
1 · Reply
Tommyj1014
Tommyj1014 Jan. 12 at 10:23 PM
$IPIX 25,000,000
1 · Reply
Tommyj1014
Tommyj1014 Jan. 12 at 9:08 PM
$IPIX my heart...
0 · Reply
Tommyj1014
Tommyj1014 Jan. 12 at 9:07 PM
$IPIX Quit playing games with my heart...
1 · Reply
Shelby500
Shelby500 Jan. 12 at 4:24 PM
$IPIX shorting it again like homeless people lol go ahead bring it up so i can smashed it in your face . i tried to teach you but still bums people told me you idiots are back i dont mess with this but since you guys are back ill slap right back at ya
0 · Reply
Tommyj1014
Tommyj1014 Jan. 8 at 6:23 PM
$IPIX Sold for 💯 😂
1 · Reply
Nik_CA
Nik_CA Jan. 8 at 4:17 PM
$IPIX Nothing to look at🤔
1 · Reply
fit007
fit007 Jan. 8 at 1:50 PM
$IPIX Looks like Kevetrin turns up in many recent published patents. Does IPIX still own the rights to Kevetrin?
0 · Reply
Tommyj1014
Tommyj1014 Jan. 5 at 9:12 PM
$IPIX .l.
0 · Reply
Latest News on IPIX
No data available.
toolajittooquit
toolajittooquit Jan. 20 at 3:47 PM
$IPIX 2026 will be the year to finally write off this stock.
1 · Reply
fit007
fit007 Jan. 13 at 6:26 PM
$IPIX Looks like brilacidin is on this report. https://neuinfo.org/data/record/nlx_144509-1/RRID:SCR_008143/resolver/pdf&i=rrid:scr_008143
1 · Reply
Tommyj1014
Tommyj1014 Jan. 12 at 10:23 PM
$IPIX 25,000,000
1 · Reply
Tommyj1014
Tommyj1014 Jan. 12 at 9:08 PM
$IPIX my heart...
0 · Reply
Tommyj1014
Tommyj1014 Jan. 12 at 9:07 PM
$IPIX Quit playing games with my heart...
1 · Reply
Shelby500
Shelby500 Jan. 12 at 4:24 PM
$IPIX shorting it again like homeless people lol go ahead bring it up so i can smashed it in your face . i tried to teach you but still bums people told me you idiots are back i dont mess with this but since you guys are back ill slap right back at ya
0 · Reply
Tommyj1014
Tommyj1014 Jan. 8 at 6:23 PM
$IPIX Sold for 💯 😂
1 · Reply
Nik_CA
Nik_CA Jan. 8 at 4:17 PM
$IPIX Nothing to look at🤔
1 · Reply
fit007
fit007 Jan. 8 at 1:50 PM
$IPIX Looks like Kevetrin turns up in many recent published patents. Does IPIX still own the rights to Kevetrin?
0 · Reply
Tommyj1014
Tommyj1014 Jan. 5 at 9:12 PM
$IPIX .l.
0 · Reply
Techallure
Techallure Dec. 27 at 6:01 PM
$IPIX My guess ? Alice Gottlieb was involved with Brilacidin Scott Gottlieb resigns from FDA and was tied to Pfizer Alice Gottlieb was tied to Pfizer Jane Harness ex CEO of IPIX and Pfizer certainly has agendas good or bad vs Brilacidin New FDA … new rules … corruption being removed Turtle moves out of the rabbit hole Be Prepared
3 · Reply
harmeyerc
harmeyerc Dec. 27 at 1:58 PM
$IPIX BeMed is buying so they can execute the reverse merger. That's my guess.
1 · Reply
Nik_CA
Nik_CA Dec. 26 at 10:20 PM
$IPIX Interestingly, a search on ClinicalTrials. gov doesn't return any active CT. https://clinicaltrials.gov/search?spons=Innovation%20Pharmaceuticals,%20Inc.&viewType=Table Maybe, CT is being done under other jurisdiction and/or with a different sponsor. Any thoughts?
1 · Reply
Tommyj1014
Tommyj1014 Dec. 26 at 9:05 PM
$IPIX one day y'all
0 · Reply
WallStreetIsNotEasy
WallStreetIsNotEasy Dec. 26 at 8:59 PM
$IPIX my avg is 0.04 with 2+ million shares I’m not worried at all
1 · Reply
WallStreetIsNotEasy
WallStreetIsNotEasy Dec. 26 at 8:06 PM
$IPIX We are getting closer imo
0 · Reply
Techallure
Techallure Dec. 26 at 5:20 PM
$IPIX Anyone who purchased at .10 should hold for your return to even land and anything more … is a much bigger bonus Be prepared
1 · Reply
Nik_CA
Nik_CA Dec. 26 at 4:09 PM
$IPIX With successful completion of P2 trials for oral mucositis in cancer patients and for skin infection, there can be three potential outcomes: 1. Initiate P3 on their own but they don’t have funding to conduct on their own. 2. Strike a partnership deal just for this specific product progress with milestone payments plus royalties 3. Accept BO offer and sell the company My order starts with highest probability is 3 and then 2.
0 · Reply
Nik_CA
Nik_CA Dec. 26 at 6:33 AM
$IPIX @fit007 Thanks mate! The following excerpt from the published article appears very promising “Brilacidin has completed phase II trials for oral mucositis in cancer patients and for skin infections. It demonstrated favorable safety and efficacy profiles, with particular effectiveness against Gram-positive bacteria. Brilacidin’s ability to modulate pro-inflammatory cytokines and its stability under physiological conditions have positioned it as a potential dualpurpose therapeutic agent, combining antimicrobial action with tissue protection.”
0 · Reply
fit007
fit007 Dec. 26 at 12:44 AM
$IPIX https://www.gavinpublishers.com/article/view/cationic-antimicrobial-peptides-current-applications-and-future-perspectives-in-human-medicine
0 · Reply
Tommyj1014
Tommyj1014 Dec. 23 at 6:03 PM
$IPIX I wonder if they think this has gone unoticed???
1 · Reply
fit007
fit007 Dec. 23 at 3:19 PM
$IPIX https://journals.physiology.org/doi/epdf/10.1152/ajpcell.00080.2022
0 · Reply